Noor Ul Ain Rehman
Tue, March 31, 2026 astatine 10:06 AM CDT 2 min read
Reuters reported the aforesaid time that ImmunityBio Inc. (NASDAQ:IBRX) has been directed by the FDA to cease the TV advertisement and podcast oregon instrumentality it down, and besides taxable a written effect wrong 15 moving days addressing the concerns described successful the letter. The institution told Reuters successful an email that the process of reviewing the agency’s missive has begun, and it aims to respond wrong the requested timeframe to address the matter.
ImmunityBio, Inc. (NASDAQ:IBRX) is simply a clinical-stage immunotherapy institution that develops next-generation therapies to dainty crab and infectious diseases. Its immunotherapy level activates the adaptive and innate immune systems to make semipermanent immunological memory.
While we admit the imaginable of IBRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey connected Google News.

2 days ago
3



.png)

English (CA) ·
English (US) ·
Spanish (MX) ·